Inactivation of ANGPTL3 reduces hepatic VLDL-triglyceride secretion

Journal of Lipid Research

Volumn 56, Issue 7, 2015, Pages 1296-1307

  Wang, Yan ^a,b   Gusarova, Viktoria ^c   Banfi, Serena ^a   Gromada, Jesper ^c   Cohen, Jonathan C ^a   Hobbs, Helen H ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c REGENERON PHARMACEUTICALS INC   (United States)

Author keywords

Angiopoietin like protein 3; Cholesterol; Dyslipidemias; Lipase endothelial; Lipase lipoprotein; Very low density lipoprotein

Indexed keywords

ANGIOPOIETIN; ANGIOPOIETIN LIKE PROTEIN 3; APOLIPOPROTEIN B100; APOLIPOPROTEIN E; EVINACUMAB; FATTY ACID; IODINE 125; LOW DENSITY LIPOPROTEIN RECEPTOR; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN; ANGPTL3 PROTEIN, HUMAN; ANGPTL3 PROTEIN, MOUSE; CHOLESTEROL; LRP1 PROTEIN, MOUSE; MONOCLONAL ANTIBODY; SYNDECAN 1; TUMOR SUPPRESSOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; APOE GENE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FATTY ACID OXIDATION; FATTY ACID SYNTHESIS; GENE INACTIVATION; LDLR GENE; LRP1 GENE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN METABOLISM; PROTEIN SECRETION; RABBIT; SDC1 GENE; ANIMAL; BLOOD; DEFICIENCY; GENE SILENCING; GENETICS; HUMAN; IMMUNOLOGY; LIVER; SECRETION (PROCESS);

ANGIOPOIETINS; ANIMALS; ANTIBODIES, MONOCLONAL; APOLIPOPROTEINS E; CHOLESTEROL; GENE SILENCING; HUMANS; LIPOPROTEINS, VLDL; LIVER; MALE; MICE; RABBITS; RECEPTORS, LDL; SYNDECAN-1; TRIGLYCERIDES; TUMOR SUPPRESSOR PROTEINS;

EID: 84937157286     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M054882     Document Type: Article

References (59)

1. Expert Dyslipidemia Panel of the International Atherosclerosis Society Panel. 2014. An International Atherosclerosis Society Position Paper: global recommendations for the management of dyslipidemia-full report. J. Clin. Lipidol. 8: 29-60.
2. Baigent, C., A. Keech, P. M. Kearney, L. Blackwell, G. Buck, C. Pollicino, A. Kirby, T. Sourjina, R. Peto, R. Collins, et al. 2005. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 366: 1267-1278.
3. Linton, M. F., R. V. Farese, Jr., and S. G. Young. 1993. Familial hypobetalipoproteinemia. J. Lipid Res. 34: 521-541.
4. Wetterau, J. R., L. P. Aggerbeck, M. E. Bouma, C. Eisenberg, A. Munck, M. Hermier, J. Schmitz, G. Gay, D. J. Rader, and R. E. Gregg. 1992. Absence of microsomal triglyceride transfer protein in individuals with abetalipoproteinemia. Science. 258: 999-1001.
5. Stein, E. A., R. Dufour, C. Gagne, D. Gaudet, C. East, J. M. Donovan, W. Chin, D. L. Tribble, and M. McGowan. 2012. Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease. Circulation. 126: 2283-2292.
6. Cuchel, M., and D. J. Rader. 2013. Microsomal transfer protein inhibition in humans. Curr. Opin. Lipidol. 24: 246-250.
7. Cohen, J. C., E. Boerwinkle, T. H. Mosley, and H. H. Hobbs. 2006. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N. Engl. J. Med. 354: 1264-1272.
8. Stein, E. A., S. Mellis, G. D. Yancopoulos, N. Stahl, D. Logan, W. B. Smith, E. Lisbon, M. Gutierrez, C. Webb, R. Wu, et al. 2012. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N. Engl. J. Med. 366: 1108-1118.
9. Weinreich, M., and W. H. Frishman. 2014. Antihyperlipidemic therapies targeting PCSK9. Cardiol. Rev. 22: 140-146.
10. Musunuru, K., J. P. Pirruccello, R. Do, G. M. Peloso, C. Guiducci, C. Sougnez, K. V. Garimella, S. Fisher, J. Abreu, A. J. Barry, et al. 2010. Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia. N. Engl. J. Med. 363: 2220-2227.
11. Pisciotta, L., E. Favari, L. Magnolo, S. Simonelli, M. P. Adorni, R. Sallo, T. Fancello, I. Zavaroni, D. Ardigo, F. Bernini, et al. 2012. Characterization of three kindreds with familial combined hypolipidemia caused by loss-of-function mutations of ANGPTL3. Circ Cardiovasc Genet. 5: 42-50.
12. Minicocci, I., A. Montali, M. R. Robciuc, F. Quagliarini, V. Censi, G. Labbadia, C. Gabiati, G. Pigna, M. L. Sepe, F. Pannozzo, et al. 2012. Mutations in the ANGPTL3 gene and familial combined hypolipidemia: a clinical and biochemical characterization. J. Clin. Endocrinol. Metab. 97: E1266-E1275.
13. Arca, M., I. Minicocci, and M. Maranghi. 2013. The angiopoietin-like protein 3: a hepatokine with expanding role in metabolism. Curr. Opin. Lipidol. 24: 313-320.
14. Shimizugawa, T., M. Ono, M. Shimamura, K. Yoshida, Y. Ando, R. Koishi, K. Ueda, T. Inaba, H. Minekura, T. Kohama, et al. 2002. ANGPTL3 decreases very low density lipoprotein triglyceride clearance by inhibition of lipoprotein lipase. J. Biol. Chem. 277: 33742-33748.
15. Shimamura, M., M. Matsuda, H. Yasumo, M. Okazaki, K. Fujimoto, K. Kono, T. Shimizugawa, Y. Ando, R. Koishi, T. Kohama, et al. 2007. Angiopoietin-like protein3 regulates plasma HDL cholesterol through suppression of endothelial lipase. Arterioscler. Thromb. Vasc. Biol. 27: 366-372.
16. Jin, W., X. Wang, J. S. Millar, T. Quertermous, G. H. Rothblat, J. M. Glick, and D. J. Rader. 2007. Hepatic proprotein convertases modulate HDL metabolism. Cell Metab. 6: 129-136.
17. Robciuc, M. R., M. Maranghi, A. Lahikainen, D. Rader, A. Bensadoun, K. Oorni, J. Metso, I. Minicocci, E. Ciociola, F. Ceci, et al. 2013. Angptl3 deficiency is associated with increased insulin sensitivity, lipoprotein lipase activity, and decreased serum free fatty acids. Arterioscler. Thromb. Vasc. Biol. 33: 1706-1713. [Erratum. 2013. Arterioscler. Thromb. Vasc. Biol. 33: e124.]
18. Kane, J. P., and R. J. Havel. 2001. Structure and metabolism of plasma lipoproteins. In Metabolic and Molecular Bases of Inherited Disease. C. R. Scriver, A. L. Beaudet, D. Valle, et al., editors. McGraw Hill, New York. 2717-2752.
19. Brown, M. S., and J. L. Goldstein. 1976. Receptor-mediated control of cholesterol metabolism. Science. 191: 150-154.
20. Kowal, R. C., J. Herz, J. L. Goldstein, V. Esser, and M. S. Brown. 1989. Low density lipoprotein receptor-related protein mediates uptake of cholesteryl esters derived from apoprotein E-enriched lipoproteins. Proc. Natl. Acad. Sci. USA. 86: 5810-5814.
21. Stanford, K. I., J. R. Bishop, E. M. Foley, J. C. Gonzales, I. R. Niesman, J. L. Witztum, and J. D. Esko. 2009. Syndecan-1 is the primary heparan sulfate proteoglycan mediating hepatic clearance of triglyceride-rich lipoproteins in mice. J. Clin. Invest. 119: 3236-3245.
22. Ando, Y., T. Shimizugawa, S. Takeshita, M. Ono, M. Shimamura, R. Koishi, and H. Furukawa. 2003. A decreased expression of angiopoietin-like 3 is protective against atherosclerosis in apoE-deficient mice. J. Lipid Res. 44: 1216-1223.
23. Lee, E. C., U. Desai, G. Gololobov, S. Hong, X. Feng, X. C. Yu, J. Gay, N. Wilganowski, C. Gao, L. L. Du, et al. 2009. Identification of a new functional domain in angiopoietin-like 3 (ANGPTL3) and angiopoietin-like 4 (ANGPTL4) involved in binding and inhibition of lipoprotein lipase (LPL). J. Biol. Chem. 284: 13735-13745.
24. Gusarova, V., C. A. Alexa, Y. Wang, A. Rafique, J. H. Kim, D. Buckler, I. J. Mintah, L. M. Shihanian, J. C. Cohen, H. H. Hobbs, et al. 2015. ANGPTL3 blockade with a human monoclonal antibody reduces plasma lipids in dyslipidemic mice and monkeys. J. Lipid Res. 56: 1308-1317.
25. Park, P. W., G. B. Pier, M. T. Hinkes, and M. Bernfield. 2001. Exploitation of syndecan-1 shedding by Pseudomonas aeruginosa enhances virulence. Nature. 411: 98-102.
26. Rohlmann, A., M. Gotthardt, R. E. Hammer, and J. Herz. 1998. Inducible inactivation of hepatic LRP gene by cre-mediated recombination confirms role of LRP in clearance of chylomicron remnants. J. Clin. Invest. 101: 689-695.
27. Wang, Y., F. Quagliarini, V. Gusarova, J. Gromada, D. M. Valenzuela, J. C. Cohen, and H. H. Hobbs. 2013. Mice lacking ANGPTL8 (Betatrophin) manifest disrupted triglyceride metabolism without impaired glucose homeostasis. Proc. Natl. Acad. Sci. USA. 110: 16109-16114.
28. Quagliarini, F., Y. Wang, J. Kozlitina, N. V. Grishin, R. Hyde, E. Boerwinkle, D. M. Valenzuela, A. J. Murphy, J. C. Cohen, and H. H. Hobbs. 2012. Atypical angiopoietin-like protein that regulates ANGPTL3. Proc. Natl. Acad. Sci. USA. 109: 19751-19756.
29. Millar, J. S., D. A. Cromley, M. G. McCoy, D. J. Rader, and J. T. Billheimer. 2005. Determining hepatic triglyceride production in mice: comparison of poloxamer 407 with Triton WR-1339. J. Lipid Res. 46: 2023-2028.
30. Ota, T., C. Gayet, and H. N. Ginsberg. 2008. Inhibition of apolipoprotein B100 secretion by lipid-induced hepatic endoplasmic reticulum stress in rodents. J. Clin. Invest. 118: 316-332.
31. Havel, R. J., H. A. Eder, and J. H. Bragdon. 1955. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J. Clin. Invest. 34: 1345-1353.
32. Goldstein, J. L., S. K. Basu, and M. S. Brown. 1983. Receptor-mediated endocytosis of low-density lipoprotein in cultured cells. Methods Enzymol. 98: 241-260.
33. Oakes, N. D., A. Kjellstedt, G. B. Forsberg, T. Clementz, G. Camejo, S. M. Furler, E. W. Kraegen, M. Olwegard-Halvarsson, A. B. Jenkins, and B. Ljung. 1999. Development and initial evaluation of a novel method for assessing tissue-specific plasma free fatty acid utilization in vivo using (R)-2-bromopalmitate tracer. J. Lipid Res. 40: 1155-1169.
34. Shimano, H., J. D. Horton, R. E. Hammer, I. Shimomura, M. S. Brown, and J. L. Goldstein. 1996. Overproduction of cholesterol and fatty acids causes massive liver enlargement in transgenic mice expressing truncated SREBP-1a. J. Clin. Invest. 98: 1575-1584.
35. Pike, L. S., A. L. Smift, N. J. Croteau, D. A. Ferrick, and M. Wu. 2011. Inhibition of fatty acid oxidation by etomoxir impairs NADPH production and increases reactive oxygen species resulting in ATP depletion and cell death in human glioblastoma cells. Biochim. Biophys. Acta. 1807: 726-734.
36. Goldstein, J. L., and M. S. Brown. 2009. The LDL receptor. Arterioscler. Thromb. Vasc. Biol. 29: 431-438.
37. Herz, J., and D. K. Strickland. 2001. LRP: a multifunctional scavenger and signaling receptor. J. Clin. Invest. 108: 779-784.
38. Foley, E. M., and J. D. Esko. 2010. Hepatic heparan sulfate proteoglycans and endocytic clearance of triglyceride-rich lipoproteins. Prog. Mol. Biol. Transl. Sci. 93: 213-233.
39. Bartelt, A., O. T. Bruns, R. Reimer, H. Hohenberg, H. Ittrich, K. Peldschus, M. G. Kaul, U. I. Tromsdorf, H. Weller, C. Waurisch, et al. 2011. Brown adipose tissue activity controls triglyceride clearance. Nat. Med. 17: 200-205.
40. Köster, A., Y. B. Chao, M. Mosior, A. Ford, P. A. Gonzalez-DeWhitt, J. E. Hale, D. Li, Y. Qiu, C. C. Fraser, D. D. Yang, et al. 2005. Transgenic angiopoietin-like (angptl)4 overexpression and targeted disruption of angptl4 and angptl3: regulation of triglyceride metabolism. Endocrinology. 146: 4943-4950.
41. Shimada, M., S. Ishibashi, T. Inaba, H. Yagyu, K. Harada, J. I. Osuga, K. Ohashi, Y. Yazaki, and N. Yamada. 1996. Suppression of diet-induced atherosclerosis in low density lipoprotein receptor knockout mice overexpressing lipoprotein lipase. Proc. Natl. Acad. Sci. USA. 93: 7242-7246.
42. Zsigmond, E., K. Kobayashi, K. W. Tzung, L. Li, Y. Fuke, and L. Chan. 1997. Adenovirus-mediated gene transfer of human lipoprotein lipase ameliorates the hyperlipidemias associated with apolipoprotein E and LDL receptor deficiencies in mice. Hum. Gene Ther. 8: 1921-1933.
43. Hu, L., C. C. van der Hoogt, S. M. Espirito Santo, R. Out, K. E. Kypreos, B. J. van Vlijmen, T. J. Van Berkel, J. A. Romijn, L. M. Havekes, K. W. van Dijk, et al. 2008. The hepatic uptake of VLDL in lrp-ldlr-/-vldlr-/- mice is regulated by LPL activity and involves proteoglycans and SR-BI. J. Lipid Res. 49: 1553-1561.
44. Adachi, H., T. Kondo, G. Y. Koh, A. Nagy, Y. Oike, and E. Araki. 2011. Angptl4 deficiency decreases serum triglyceride levels in low-density lipoprotein receptor knockout mice and streptozotocin-induced diabetic mice. Biochem. Biophys. Res. Commun. 409: 177-180.
45. Olin, K. L., S. Potter-Perigo, P. H. Barrett, T. N. Wight, and A. Chait. 1999. Lipoprotein lipase enhances the binding of native and oxidized low density lipoproteins to versican and biglycan synthesized by cultured arterial smooth muscle cells. J. Biol. Chem. 274: 34629-34636.
46. Merkel, M., Y. Kako, H. Radner, I. S. Cho, R. Ramasamy, J. D. Brunzell, I. J. Goldberg, and J. L. Breslow. 1998. Catalytically inactive lipoprotein lipase expression in muscle of transgenic mice increases very low density lipoprotein uptake: direct evidence that lipoprotein lipase bridging occurs in vivo. Proc. Natl. Acad. Sci. USA. 95: 13841-13846.
47. Felts, J. M., H. Itakura, and R. T. Crane. 1975. The mechanism of assimilation of constituents of chylomicrons, very low density lipoproteins and remnants-a new theory. Biochem. Biophys. Res. Commun. 66: 1467-1475.
48. Sonnenburg, W. K., D. Yu, E. C. Lee, W. Xiong, G. Gololobov, B. Key, J. Gay, N. Wilganowski, Y. Hu, S. Zhao, et al. 2009. GPIHBP1 stabilizes lipoprotein lipase and prevents its inhibition by angiopoietin-like 3 and angiopoietin-like 4. J. Lipid Res. 50: 2421-2429.
49. Beigneux, A. P., B. S. Davies, A. Bensadoun, L. G. Fong, and S. G. Young. 2009. GPIHBP1, a GPI-anchored protein required for the lipolytic processing of triglyceride-rich lipoproteins. J. Lipid Res. 50 (Suppl) : S57-S62.
50. Weinstein, M. M., L. Yin, A. P. Beigneux, B. S. Davies, P. Gin, K. Estrada, K. Melford, J. R. Bishop, J. D. Esko, G. M. Dallinga-Thie, et al. 2008. Abnormal patterns of lipoprotein lipase release into the plasma in GPIHBP1-deficient mice. J. Biol. Chem. 283: 34511-34518.
51. Broedl, U. C., C. Maugeais, J. S. Millar, W. Jin, R. E. Moore, I. V. Fuki, D. Marchadier, J. M. Glick, and D. J. Rader. 2004. Endothelial lipase promotes the catabolism of ApoB-containing lipoproteins. Circ. Res. 94: 1554-1561.
52. Raabe, M., M. M. Veniant, M. A. Sullivan, C. H. Zlot, J. Bjorkegren, L. B. Nielsen, J. S. Wong, R. L. Hamilton, and S. G. Young. 1999. Analysis of the role of microsomal triglyceride transfer protein in the liver of tissue-specific knockout mice. J. Clin. Invest. 103: 1287-1298.
53. Tanoli, T., P. Yue, D. Yablonskiy, and G. Schonfeld. 2004. Fatty liver in familial hypobetalipoproteinemia: roles of the APOB defects, intra-abdominal adipose tissue, and insulin sensitivity. J. Lipid Res. 45: 941-947.
54. Inaba, T., M. Matsuda, M. Shimamura, N. Takei, N. Terasaka, Y. Ando, H. Yasumo, R. Koishi, M. Makishima, and I. Shimomura. 2003. Angiopoietin-like protein 3 mediates hypertriglyceridemia induced by the liver X receptor. J. Biol. Chem. 278: 21344-21351.
55. Yue, P., T. Tanoli, O. Wilhelm, B. Patterson, D. Yablonskiy, and G. Schonfeld. 2005. Absence of fatty liver in familial hypobetalipoproteinemia linked to chromosome 3p21. Metabolism. 54: 682-688.
56. Koishi, R., Y. Ando, M. Ono, M. Shimamura, H. Yasumo, T. Fujiwara, H. Horikoshi, and H. Furukawa. 2002. Angptl3 regulates lipid metabolism in mice. Nat. Genet. 30: 151-157.
57. Zhang, Y. L., A. Hernandez-Ono, C. Ko, K. Yasunaga, L. S. Huang, and H. N. Ginsberg. 2004. Regulation of hepatic apolipoprotein B-lipoprotein assembly and secretion by the availability of fatty acids. I. Differential response to the delivery of fatty acids via albumin or remnant-like emulsion particles. J. Biol. Chem. 279: 19362-19374.
58. Jong, M. C., P. C. Rensen, V. E. Dahlmans, H. van der Boom, T. J. van Berkel, and L. M. Havekes. 2001. Apolipoprotein C-III deficiency accelerates triglyceride hydrolysis by lipoprotein lipase in wild-type and apoE knockout mice. J. Lipid Res. 42: 1578-1585.
59. Gaudet, D., D. Brisson, K. Tremblay, V. J. Alexander, W. Singleton, S. G. Hughes, R. S. Geary, B. F. Baker, M. J. Graham, R. M. Crooke, et al. 2014. Targeting APOC3 in the familial chylomicronemia syndrome. N. Engl. J. Med. 371: 2200-2206.